Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 3.85
Key Takeaways
Risk factor
Good trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overvalued on P/FCF.
Data is available to registered users only
Buy
Sell